M&A Deal Summary

Argentum Acquires TheraBond

On September 5, 2017, Argentum acquired life science company TheraBond from Alliqua for 4M USD

Acquisition Highlights
  • This is Argentum’s 1st transaction in the Life Science sector.
  • This is Argentum’s largest (disclosed) transaction.
  • This is Argentum’s 1st transaction in the United States.
  • This is Argentum’s 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2017-09-05
Target TheraBond
Sector Life Science
Buyer(s) Argentum
Sellers(s) Alliqua
Deal Type Divestiture
Deal Value 4M USD

Target

TheraBond

Yardley, Pennsylvania, United States
The TheraBond® product line is based on a proprietary and patented manufacturing process where silver is bonded to the entire surface of all fibers of the TheraBond® dressing. When TheraBond® products are placed on the wound, bioactive ionic silver is released in the dressing at a controlled rate, promoting an optimal wound healing environment by creating an antimicrobial barrier to more effectively protect the wound.

Search 199,712 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Argentum

Geneva, Illinois, United States

Category Company
Founded 2001
Sector Medical Products
DESCRIPTION

Argentum is a manufacturer and sells innovative wound care products across a wide number of clinical applications, including the Silverlon® (“Silverlon”) brand, its rapidly-growing, proprietary range of silver-based antimicrobial products. The core platform technology in Silverlon is a uniquely designed silver-plated nylon matrix that provides the powerful antimicrobial properties of silver ions in the dressing without staining the skin and without increasing bioburden. Silverlon dressings are used today by surgeons and other healthcare professionals around the world on surgical wounds, burns, chronic wounds, IV catheter-related wounds, and for negative pressure wound therapy. Argentum was founded in 2001 and is based in Geneva, Illinois.


DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 2
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-01-18 Anacapa Technologies

San Dimas, California, United States

Anacapa Technologies is an innovator in the formulation of antimicrobial skin & wound care products. The company's Anasept Antimicrobial Skin & Wound Cleanser and Gel is a powerful board-spectrum, a topical antimicrobial that is long-acting, crystal clear, and highly-viscous, available in a tube as a hydrogel or as a liquid in spray and pour bottles. Its offering has been expanded to serve the Veterinarian market. Anacapa Technologies is based in San Dimas, California.

Buy -

Seller(S) 1

SELLER

Alliqua

Langhorne, Pennsylvania, United States

Category Company
Sector Medical Products
Revenue 2M USD (2018)
DESCRIPTION

Alliqua provides a custom manufacturing solution to partners in the medical device; cosmetics; and OTC industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot GMP manufacturing facility in Langhorne, Pa., allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries.


DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-05 Soluble Systems

Newport News, Virginia, United States

Soluble Systems LLC is a manufacturer and/or distributor of a line of advanced wound care products under the brand names TheraSkin and TheraGauze. Soluble’s lead product, TheraSkin®, is a cryopreserved human skin allograft for non-responsive chronic wounds which competes in the fast growing biologic market of advanced wound care.

Buy $35M